CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation

Mariaelvina Sala, Daniela Braida, Luca Pucci, Irene Manfredi, Michael J. Marks, Charles R. Wageman, Sharon R. Grady, Barbara Loi, Sergio Fucile, Francesca Fasoli, Michele Zoli, Bruno Tasso, Fabio Sparatore, Francesco Clementi, Cecilia Gotti

Research output: Contribution to journalArticle

Abstract

Background and Purpose Many of the addictive and rewarding effects of nicotine are due to its actions on the neuronal nicotinic ACh receptor (nAChR) subtypes expressed in dopaminergic mesocorticolimbic cells. The partial agonists, cytisine and varenicline, are helpful smoking cessation aids. These drugs have a number of side effects that limit their usefulness. The aim of this study was to investigate the preclinical pharmacology of the cytisine dimer1,2-bisN-cytisinylethane (CC4). Experimental Approach The effects of CC4 on nAChRs were investigated using in vitro assays and animal behaviours. Key Results When electrophysiologically tested using heterologously expressed human subtypes, CC4 was less efficacious than cytisine on neuronal α4β2, α3β4, α7 and muscle-type receptors, and had no effect on 5-hydroxytryptamine3 receptors. Acting through α4β2 and α6β2 nAChRs, CC4 is a partial agonist of nAChR-mediated striatal dopamine release and, when co-incubated with nicotine, prevented nicotine's maximal effect on this response. In addition, it had low affinity for, and was less efficacious than nicotine and cytisine on the α3β4 and α7-nAChR subtypes. Like cytisine and nicotine, CC4-induced conditioned place preference (CPP), and its self-Administration shows an inverted-U dose-response curve. Pretreatment with non-reinforcing doses of CC4 significantly reduced nicotine-induced self-Administration and CPP without affecting motor functions. Conclusion and Implications Our in vitro and in vivo findings reveal that CC4 selectively reduces behaviours associated with nicotine addiction consistent with the partial agonist selectivity of CC4 for β2-nAChRs. The results support the possible development of CC4 or its derivatives as a promising drug for tobacco smoking cessation.

Original languageEnglish
Pages (from-to)835-849
Number of pages15
JournalBritish Journal of Pharmacology
Volume168
Issue number4
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Tobacco Use Cessation
Nicotinic Receptors
Cholinergic Receptors
Smoking Cessation
Nicotine
Smoking
Self Administration
Corpus Striatum
Animal Behavior
cytisine
Pharmaceutical Preparations
Dopamine
Pharmacology
Muscles

Keywords

  • α4β2 and α6β2 nicotinic Ach receptor subtypes
  • 5-hydroxytryptamine3 receptors
  • conditioned place preference
  • neurotransmitter release
  • partial agonist
  • rat
  • self-Administration

ASJC Scopus subject areas

  • Pharmacology

Cite this

CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation. / Sala, Mariaelvina; Braida, Daniela; Pucci, Luca; Manfredi, Irene; Marks, Michael J.; Wageman, Charles R.; Grady, Sharon R.; Loi, Barbara; Fucile, Sergio; Fasoli, Francesca; Zoli, Michele; Tasso, Bruno; Sparatore, Fabio; Clementi, Francesco; Gotti, Cecilia.

In: British Journal of Pharmacology, Vol. 168, No. 4, 02.2013, p. 835-849.

Research output: Contribution to journalArticle

Sala, M, Braida, D, Pucci, L, Manfredi, I, Marks, MJ, Wageman, CR, Grady, SR, Loi, B, Fucile, S, Fasoli, F, Zoli, M, Tasso, B, Sparatore, F, Clementi, F & Gotti, C 2013, 'CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation', British Journal of Pharmacology, vol. 168, no. 4, pp. 835-849. https://doi.org/10.1111/j.1476-5381.2012.02204.x
Sala, Mariaelvina ; Braida, Daniela ; Pucci, Luca ; Manfredi, Irene ; Marks, Michael J. ; Wageman, Charles R. ; Grady, Sharon R. ; Loi, Barbara ; Fucile, Sergio ; Fasoli, Francesca ; Zoli, Michele ; Tasso, Bruno ; Sparatore, Fabio ; Clementi, Francesco ; Gotti, Cecilia. / CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation. In: British Journal of Pharmacology. 2013 ; Vol. 168, No. 4. pp. 835-849.
@article{925c23ddc64b47de9c63d0f0d530d826,
title = "CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation",
abstract = "Background and Purpose Many of the addictive and rewarding effects of nicotine are due to its actions on the neuronal nicotinic ACh receptor (nAChR) subtypes expressed in dopaminergic mesocorticolimbic cells. The partial agonists, cytisine and varenicline, are helpful smoking cessation aids. These drugs have a number of side effects that limit their usefulness. The aim of this study was to investigate the preclinical pharmacology of the cytisine dimer1,2-bisN-cytisinylethane (CC4). Experimental Approach The effects of CC4 on nAChRs were investigated using in vitro assays and animal behaviours. Key Results When electrophysiologically tested using heterologously expressed human subtypes, CC4 was less efficacious than cytisine on neuronal α4β2, α3β4, α7 and muscle-type receptors, and had no effect on 5-hydroxytryptamine3 receptors. Acting through α4β2 and α6β2 nAChRs, CC4 is a partial agonist of nAChR-mediated striatal dopamine release and, when co-incubated with nicotine, prevented nicotine's maximal effect on this response. In addition, it had low affinity for, and was less efficacious than nicotine and cytisine on the α3β4 and α7-nAChR subtypes. Like cytisine and nicotine, CC4-induced conditioned place preference (CPP), and its self-Administration shows an inverted-U dose-response curve. Pretreatment with non-reinforcing doses of CC4 significantly reduced nicotine-induced self-Administration and CPP without affecting motor functions. Conclusion and Implications Our in vitro and in vivo findings reveal that CC4 selectively reduces behaviours associated with nicotine addiction consistent with the partial agonist selectivity of CC4 for β2-nAChRs. The results support the possible development of CC4 or its derivatives as a promising drug for tobacco smoking cessation.",
keywords = "α4β2 and α6β2 nicotinic Ach receptor subtypes, 5-hydroxytryptamine3 receptors, conditioned place preference, neurotransmitter release, partial agonist, rat, self-Administration",
author = "Mariaelvina Sala and Daniela Braida and Luca Pucci and Irene Manfredi and Marks, {Michael J.} and Wageman, {Charles R.} and Grady, {Sharon R.} and Barbara Loi and Sergio Fucile and Francesca Fasoli and Michele Zoli and Bruno Tasso and Fabio Sparatore and Francesco Clementi and Cecilia Gotti",
year = "2013",
month = "2",
doi = "10.1111/j.1476-5381.2012.02204.x",
language = "English",
volume = "168",
pages = "835--849",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation

AU - Sala, Mariaelvina

AU - Braida, Daniela

AU - Pucci, Luca

AU - Manfredi, Irene

AU - Marks, Michael J.

AU - Wageman, Charles R.

AU - Grady, Sharon R.

AU - Loi, Barbara

AU - Fucile, Sergio

AU - Fasoli, Francesca

AU - Zoli, Michele

AU - Tasso, Bruno

AU - Sparatore, Fabio

AU - Clementi, Francesco

AU - Gotti, Cecilia

PY - 2013/2

Y1 - 2013/2

N2 - Background and Purpose Many of the addictive and rewarding effects of nicotine are due to its actions on the neuronal nicotinic ACh receptor (nAChR) subtypes expressed in dopaminergic mesocorticolimbic cells. The partial agonists, cytisine and varenicline, are helpful smoking cessation aids. These drugs have a number of side effects that limit their usefulness. The aim of this study was to investigate the preclinical pharmacology of the cytisine dimer1,2-bisN-cytisinylethane (CC4). Experimental Approach The effects of CC4 on nAChRs were investigated using in vitro assays and animal behaviours. Key Results When electrophysiologically tested using heterologously expressed human subtypes, CC4 was less efficacious than cytisine on neuronal α4β2, α3β4, α7 and muscle-type receptors, and had no effect on 5-hydroxytryptamine3 receptors. Acting through α4β2 and α6β2 nAChRs, CC4 is a partial agonist of nAChR-mediated striatal dopamine release and, when co-incubated with nicotine, prevented nicotine's maximal effect on this response. In addition, it had low affinity for, and was less efficacious than nicotine and cytisine on the α3β4 and α7-nAChR subtypes. Like cytisine and nicotine, CC4-induced conditioned place preference (CPP), and its self-Administration shows an inverted-U dose-response curve. Pretreatment with non-reinforcing doses of CC4 significantly reduced nicotine-induced self-Administration and CPP without affecting motor functions. Conclusion and Implications Our in vitro and in vivo findings reveal that CC4 selectively reduces behaviours associated with nicotine addiction consistent with the partial agonist selectivity of CC4 for β2-nAChRs. The results support the possible development of CC4 or its derivatives as a promising drug for tobacco smoking cessation.

AB - Background and Purpose Many of the addictive and rewarding effects of nicotine are due to its actions on the neuronal nicotinic ACh receptor (nAChR) subtypes expressed in dopaminergic mesocorticolimbic cells. The partial agonists, cytisine and varenicline, are helpful smoking cessation aids. These drugs have a number of side effects that limit their usefulness. The aim of this study was to investigate the preclinical pharmacology of the cytisine dimer1,2-bisN-cytisinylethane (CC4). Experimental Approach The effects of CC4 on nAChRs were investigated using in vitro assays and animal behaviours. Key Results When electrophysiologically tested using heterologously expressed human subtypes, CC4 was less efficacious than cytisine on neuronal α4β2, α3β4, α7 and muscle-type receptors, and had no effect on 5-hydroxytryptamine3 receptors. Acting through α4β2 and α6β2 nAChRs, CC4 is a partial agonist of nAChR-mediated striatal dopamine release and, when co-incubated with nicotine, prevented nicotine's maximal effect on this response. In addition, it had low affinity for, and was less efficacious than nicotine and cytisine on the α3β4 and α7-nAChR subtypes. Like cytisine and nicotine, CC4-induced conditioned place preference (CPP), and its self-Administration shows an inverted-U dose-response curve. Pretreatment with non-reinforcing doses of CC4 significantly reduced nicotine-induced self-Administration and CPP without affecting motor functions. Conclusion and Implications Our in vitro and in vivo findings reveal that CC4 selectively reduces behaviours associated with nicotine addiction consistent with the partial agonist selectivity of CC4 for β2-nAChRs. The results support the possible development of CC4 or its derivatives as a promising drug for tobacco smoking cessation.

KW - α4β2 and α6β2 nicotinic Ach receptor subtypes

KW - 5-hydroxytryptamine3 receptors

KW - conditioned place preference

KW - neurotransmitter release

KW - partial agonist

KW - rat

KW - self-Administration

UR - http://www.scopus.com/inward/record.url?scp=84872896597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872896597&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2012.02204.x

DO - 10.1111/j.1476-5381.2012.02204.x

M3 - Article

C2 - 22957729

AN - SCOPUS:84872896597

VL - 168

SP - 835

EP - 849

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -